hepatitis b prevalence among blood donors at a tertiary care centre

advertisement
ORIGINAL ARTICLE
HEPATITIS B PREVALENCE AMONG BLOOD DONORS AT A
TERTIARY CARE CENTRE IN MYSORE
Sreenivas N1, Kunal Puri2, Shubha Jayaram3
HOW TO CITE THIS ARTICLE:
Sreenivas N, Kunal Puri, Shubha Jayaram. ”Hepatitis B prevalence among blood Donors at a Tertiary Care
Centre in Mysore”. Journal of Evidence based Medicine and Healthcare; Volume 2, Issue 9, March 02, 2015;
Page: 1328-1334.
ABSTRACT: BACKGROUND: Blood transfusion is an essential element of a health care system.
Safety of blood transfusion is of extreme importance in order to avoid any severe morbidity and
mortality in the patient. By screening donated blood units, we get a clue of the prevalence of
those infections among donor populations and consequently the safety of collected donations. It
also gives us an idea of the prevalence of the Transfusion transmissible infections (TTIs) in the
community. OBJECTIVES: To find out the sero-prevalence of TTIs namely HBV (Hepatitis B) in
the blood donor population at MMC&RI, Mysore. To stratify sero prevalence of TTIs based on the
age and sex of the donor population. METHODOLOGY: The present study was carried out in the
Blood Bank, Mysore Medical College and Research Institute, Mysore during the period from
November 2012 to May 2014 among 14075 blood donors. All the samples were screened for
hepatitis B surface antigen (HBsAg) by ELISA method. RESULTS: Out of a total of 14075 blood
donors, a total of 103 tested positive for TTIs. 94.08% were males and remaining 5.92% were
females. A majority of donors were voluntary donors (85.79%) and a majority of the donors were
between the age group of 18-39 years (78.17%). The prevalence rate of HBV in blood donors
was 0.73%. The seroprevalence in voluntary donors was 0.57% and in replacement donors was
1.75 % respectively. CONCLUSION: Voluntary blood donation is safe, compared to replacement
as high prevalence of Hepatitis B is observed in replacement donors.
KEYWORDS: Prevalence; Transfusion transmissible infections (TTI); Voluntary and Replacement
blood donors.
INTRODUCTION: Blood transfusion is an essential element of a health care system. Safety of
blood transfusion is of extreme importance in order to avoid any severe morbidity and mortality in
the patient.
By screening donated blood units, we get a clue of the prevalence of those infections
among donor populations and consequently the safety of collected donations. It also gives us an
idea of the prevalence of the Transfusion transmissible infections (TTIs) in the community.1
Despite the dramatic reduction in risk of viral transmission during the past three decades,
viral hepatitis remains a serious complication of transfusion worldwide. The discovery in 1968 that
the viremic phase of serum hepatitis could be recognized serologically2 sparked the hope that all
infectious donors could be identified. However, HBV remains a major human pathogen that
causes acute and chronic hepatitis, cirrhosis and hepatocellular carcinoma.3
Approximately 30% of the world’s population or about 2 billion persons have serological
evidence of either current or past infection with hepatitis B virus. Countries are classified based
on endemicity of hepatitis B virus (HBV) infection into high (8% or more), intermediate (2-7%) or
J of Evidence Based Med & Hlthcare, pISSN- 2349-2562, eISSN- 2349-2570/ Vol. 2/Issue 9/Mar 02, 2015
Page 1328
ORIGINAL ARTICLE
low (less than 2%) incidence countries. The prevalence of chronic HBV infection in India ranges
from 2% to 10%, as shown by different studies. India therefore comes under the intermediate to
high endemicity category. Hepatitis B infection is one of the transfusion transmissible infections;
hence, it is mandatory to test all blood donors for HBsAg.4
Screening for HBsAg in blood was initially done by immune-diffusion and Counter
immune-electrophoresis. These methods were soon replaced by more sophisticated Immuneradiometric assay (RIA) and the ELISA, which detect less than 0.5 ng of HBsAg/ml of blood.
However, taking the molecular weight of HBsAg as 3×106, 0.5 ng is equivalent to 1×107
particles. As and when better screening methods become available more studies needs to be
conducted to establish revised prevalence rates.5
Sero-prevalence of Hepatitis B in Indian donors is 0.4% (0.66% - 12%) in comparison to
0.3% in USA. Annual blood transfusion causes an estimated 16 million HBV infection.6
Various studies in Karnataka have shown the prevalence of Hepatitis B in blood donors to
be ranging from 0.3% to3.2%.7-10 There is limited literature on recent statistics of Hepatitis B
prevalence in blood donors in and around Mysore. Hence the present study to assess the
hepatitis B sero Prevalence among blood donors at a tertiary care centre in Mysore.
OBJECTIVES:
 To find out the sero-prevalence of HBV in the blood donor population at MMC & RI, Mysore.
 To stratify sero prevalence of HBsAg based on the age and sex of the donor population.
METHODOLOGY: The present study was carried out in the Blood Bank, Mysore Medical College
and Research Institute, Mysore, Karnataka during the period from November 2012 to May 2014
among 14075 blood donors. It is a cross-sectional study.
All the samples were screened for HBsAg using ELISA method. The source of data for the
present study were Donors coming for blood donation at Blood Bank, Mysore Medical College &
Research Institute, Mysore.
All blood donors during the study period were considered. Inclusion criteria were all
voluntary and replacement donors coming for blood donation during study period. Exclusion
Criteria were age less than 18 years and more than 60 years, weight less than 45 kilograms,
donors who donated blood in last three months, donors who underwent major surgery in last six
months and minor surgeries in last three months donors who did not complete one year after
tuberculosis treatment, donors who suffered from typhoid, mumps, measles, chicken pox in last
six months, those receiving any vaccination in last one month, those who suffered from malaria
during last three years or Jaundice in last one year, suffering from any one of the diseases such
as hypertension, diabetes mellitus, malignancy, asthma, epilepsy, AIDS, syphilis, bleeding
disorders and disease of heart, liver or kidney. Pregnancy, lactation, within one year of
postpartum and within six months of miscarriage.
The study was approved by the Ethical and Research Committee of Mysore Medical
College & Research Institute, Mysore. During the study period, blood donors at Blood Bank,
Mysore Medical College & Research Institute, Mysore fulfilling the inclusion criteria were included
in this study and informed consent was obtained. Detailed relevant history was taken.
J of Evidence Based Med & Hlthcare, pISSN- 2349-2562, eISSN- 2349-2570/ Vol. 2/Issue 9/Mar 02, 2015
Page 1329
ORIGINAL ARTICLE
After finding the suitability following tests were carried out.
1. Haemoglobin estimation by Automated blood counter (Sysmex).
2. HBsAg by ELISA.
All the reactive samples were repeat tested before labelling them as seropositive. Blood
was not collected from seropositive donors.
The seropositive samples were sent for the confirmatory NAT (nucleic acid amplification
techniques) testing and findings confirmed. No false positive results were seen.
STATISTICAL METHODS: The data was tabulated in Microsoft excel and prevalence was
calculated using rates, ratios and percentages and statistical analysis done to check the
significance.
RESULTS: The present study was carried out in the Blood Bank, Mysore Medical College and
Research Institute, Mysore during the period from November 2012 to May 2014. The study
includes screening tests done on 14075 donors including both voluntary and replacement blood
donors. The findings are as follows:
In the present study, 13242 (94.08%) were male blood donors and 833(5.92%) were
female blood donors. Therefore the number of male blood donors was more than female blood
donors.(Table-1).
Sex
Male
Female
Total
No. of Donors
13,242
833
14,075
Percentage
94.08%
5.92%
100%
Table 1: Gender wise distribution of Blood Donors
33.87% donors belonged to 18 to 29 years age group followed by 44.08% donors
between 30 to 39 years, 14.52% donors between 40 to 49 years and 7.53% donors between 50
to 60 years. The minimum age recorded was 18 years and maximum age was 60 years.(Table-2)
Age (Years)
18-29
30-39
40-49
50-60
Total
No. of Donors
4,767
6,205
2,043
1,060
14,075
Percentage
33.87%
44.08%
14.52%
7.53%
100.00%
Table 2: Age Wise Distribution of Blood Donors
In the present study, 12075(85.79%) were voluntary donors and 2000 (14.21%) were
replacement donors.(Table-3)
J of Evidence Based Med & Hlthcare, pISSN- 2349-2562, eISSN- 2349-2570/ Vol. 2/Issue 9/Mar 02, 2015
Page 1330
ORIGINAL ARTICLE
Type of Donor
Voluntary
Replacement
Total
Number
12,075
2,000
14075
Percentage
85.79%
14.21%
100.00%
Table 3: Distribution according to type of Donor
Out of 14075 blood samples 103 were HBsAg positive samples showing a prevalence of
0.73%. Out of 13242 male donors, 84 were hepatitis B positive (prevalence of 0.64%) and out of
833 female donors 19 were Hepatitis B positive (prevalence 2.28%) (Table-4).
Males (13,242)
Females (833)
Total
No Percentage No Percentage No Percentage
Hepatitis B 84
0.64%
19
2.28%
103
0.73%
Donor
Table 4: Prevalence of Hepatitis B Infection in donors
In the voluntary donors group 69 (0.57%) blood donors had HBsAg infection and among
replacement donors, 34 (1.75%) blood donors had HBsAg infection. (Table-5).
Disease
Hepatitis B
Voluntary(n=12,075)
No of Donors
Percentage
69
0.57%
Replacement(n=2,000)
No of Donors
Percentage
34
1.75%
Table 5: Comparison of Hepatitis B infection in Voluntary and Replacement donors
DISCUSSION: India has a population of more than 1.2 billion with 43 million HBV positive
cases.11 The prevalence of hepatitis B surface antigen (HBsAg), positivity in Indian blood donors is
0.66-12%.4 The risk of transfusion transmissible infections (TTI) has declined dramatically in
developed nations over the past two decades, primarily because of extraordinary success in
preventing HIV and other established transfusion transmitted viruses from entering the blood
supply. But same may not hold good for the developing countries.
The National Policy for Blood Transfusion Services in our country is of recent origin and
the transfusion services are hospital based and fragmented.12 Hence the present study was
carried out in the Blood Bank, Mysore Medical College and Research Institute, Mysore.
The study includes screening tests done on donors including both voluntary and
replacement blood donors. Out of these donors, youngest donor was of 18 years and the oldest
donor was of 60 years. Similar age ranges have been observed in various other studies.
There was a predominance of male donors (94.08%) in our study which is comparable to
other studies like those done by Pallavi etal (97.84%)7 and Zulfikar Ahmed etal, (91.8%).9 The
reason for less numbers of female donors could be due to social factors, being underweight and
higher incidence of anemia in women forcing a disqualification of them as potential donors. In our
J of Evidence Based Med & Hlthcare, pISSN- 2349-2562, eISSN- 2349-2570/ Vol. 2/Issue 9/Mar 02, 2015
Page 1331
ORIGINAL ARTICLE
study voluntary donors accounted for a majority of donor type. 85.79% were voluntary donors
and remaining 14.21% were replacement donors.
This can be compared with study done by Patel et al13 where 95.56% were voluntary
donors and 4.44% were replacement donors, Deshpande et al14 where79.33% were voluntary
blood donors and 20.67% were replacement donors and study by Gupta et al12 where 61.9%
voluntary and 38.1% replacement donors were studied.
In contrast predominance of replacement donors was seen in studies done by Kakkar et al
(94.7%)15, Srikrishna et al (98.5%)16 and Singh et al (84.5%).8
Voluntary blood donors are the cornerstone of a safe and adequate supply of blood and
blood products. The safest blood donors are voluntary, non-remunerated blood donors from lowrisk populations. For a safe blood service in our country, where comprehensive laboratory tests
are neither possible nor pragmatic, it is best to switch over to 100% voluntary donations, as it is
now established that only voluntary non-remunerated regular donation is the safest.17
SEROPREVALENCE OF HEPATITIS B:
 Hepatitis B is a potentially life-threatening liver infection caused by the hepatitis B virus.
 It is a major global health problem and the most serious type of viral hepatitis.
 It can cause chronic liver disease and puts people at high risk of death from cirrhosis of the
liver and liver cancer.
 Worldwide, an estimated two billion people have been infected with the hepatitis B virus
and more than 240 million have chronic (long-term) liver infections. About 600 000 people
die every year due to the acute or consequences of hepatitis B.18
 India has been placed in the intermediate zone for prevalence of hepatitis B by WHO (2 7%).4
 In previous Indian studies by Srikrishna et al,16 Sonawane et al19 and Singh et al20 the
seroprevalence of HBsAg among the blood donors was 1.86%, 4.07% and 1.8%
respectively. They concluded that voluntary donors are comparatively safe donors.
Bhattacharya et al, observed a statistically significant increase in seroprevalence of HBsAg
over of a 2 years among the blood donors in Kolkata (Eastern India). The observed
seroprevalence of HBsAg in 2005 was 1.66%.1
In our study the seroprevalence for HBsAg was 0.73% in total donors. The seroprevalence
in voluntary donors was 0.57% and in replacement donors was 1.75 % respectively which
supports the need for voluntary blood donation.
CONCLUSION: Screening of blood samples for various TTI plays an important role in preventing
hazards of various infections. It has been observed that voluntary blood donation is safe as
compared to replacement as high prevalence of HBsAg is observed in replacement donors.
Therefore, voluntary donation should be encouraged.
However, the risk of TTI cannot be eliminated completely even after mandatory testing of
blood units because of risk associated with donations during window period.With advent of
nucleic acid amplification techniques (NAT) western countries have decreased the risk of TTI to a
J of Evidence Based Med & Hlthcare, pISSN- 2349-2562, eISSN- 2349-2570/ Vol. 2/Issue 9/Mar 02, 2015
Page 1332
ORIGINAL ARTICLE
major extent. This decrease the window period and hence decrease in incidence of TTI. But the
cost effectiveness of the NAT is poor. Its high cost is of concern especially in economically
restricted countries.
Hence optimum usage of transfused blood and use of transfused blood if only necessary
should be the aim of the treating physician.
REFERENCES:
1. Bhattacharya P, Chandra PK, Datta S, et al. Significant increase in HBV, HCV, HIV and
syphilis infections among blood donors in West Bengal, Eastern India 2004-2005:
Exploratory screening reveals high frequency of occult HBV infection. World Journal of
Gastroenterology : WJG 2007; 13(27): 3730-3733.
2. Blumberg BS, Alter HJ. A "New" Antigen in Leukemia Sera. JAMA. 1965; 191(7): 541-546.
3. Ganem, D.Prince, A.M. Hepatitis B virus infection – natural history and clinical
consequences. N Engl J Med. 2004; 350: 1118–1129
4. A Kochhar, K Singh, S Kochhar, G Duggal, S Choudhary, S Pandey. A Study To Assess Trend
In Seroprevalence of Hepatitis B Virus Infection Among Blood Donors Of Southern Haryana,
India. The Internet Journal of Pathology. 2012; 13 (2).
5. etheses.saurashtrauniversity.edu/./mankad_gp_thesis_microbiology.pdf
6. Chattoraj A, Behl R, Kataria V. Infectious disease markers in blood donors. Med J Armed
Forces India. 2008; 64: 33-5.
7. P. Pallavi, C.K Ganesh, K.Jayashree, G.V Manjunath. Seroprevalence and trends in
Transfusion Transmitted Infections Among Blood Donors in a University Hospital Blood
Bank: A 5 year study; Indian J Hematol Blood Transfus (Jan-Mar 2011) 27(1): 1-6.
8. Karandeep Singh, Sudha Bhat, Shamee Shastry. Trend in seroprevalence of Hepatitis B virus
infection among blood donors of coastsl Karnataka, India.J Infect Dev Ctries 2009; 3(5):
376-379.
9. Zulfikar Ahmed, Umaru N, Shreesha K, Seroprevalence of Transfusion Transmitted
Infections Among Blood Donors In Mangalore, Medica Innovatica 2012; 1(2): 24-27.
10. Nagarkha Kulkarni. Analysis of the seroprevalence of HIV, HBsAg, HCV and syphilis
infections detected in the pre transfusion blood: A short report. IJBTI, 2012; 2:1-3.
11. Prevention of hepatitis B in India, an overview.World Health Organization. New Delhi; 2002
p. 1-32.
12. Gupta PK, Kumar H, Basannar DR, Jaiprakash M. Transfusion transmitted in infections in
armed forces: prevalence and trends. MJAFI. 2006; 62: 348–350.
13. Patel PA, Patel SP, Oza H. Seroprevalence of transfusion transmitted infections (TTIs) in
blood donors at western Ahmedabad–a secondary care hospital based study. Int J Biol Med
Res. 2012; 3(2): 1806-1810.
14. Deshpande RH, Bhosale LL, Gadgil PA, Sonawane ML. Blood Donor.s Status of HIV, HBV,
HCV and Syphilis in this Region of Marathwada, India. Journal of Krishna Institute of Medical
Sciences University July-Dec. 2012; 1(2), 111-6.
15. Kakkar N, Kaur R, Dhanoa J. voluntary donors–need for a second look. Indian J Pathol
Microbiol. 2004; 47: 381–383.
J of Evidence Based Med & Hlthcare, pISSN- 2349-2562, eISSN- 2349-2570/ Vol. 2/Issue 9/Mar 02, 2015
Page 1333
ORIGINAL ARTICLE
16. Srikrishna A, Sitalakshmi S, Damodar P. How safe are our safe donors. Indian J Pathol
Microbiol. 1999; 42: 411–416.
17. “Voluntary blood donation programme—an operational guideline,” National AIDS Control
Organisation, Ministry of Health and Family Welfare Government of India, New Delhi, India,
2007, http://www.nacoonline.org/.
18. Hepatitis B Fact sheet No 204, July 2012. World Health Organization 2012. Available from:
http://www.who.int/mediacentre/factsheets/fs204/en/index.html.
19. Sonawane BR, Birare SD, Kulkarni PV, Prevalence of seroreactivity among blood donors in
rural population. Indian J med sci, 2003; 57: 405-407.
20. Singh B, Kataria SP, Gupta R. Infectious markers in blood donors of East. Delhi: Prevalence
and trends. Indian J Pathol Microbiol. 2004; 47: 477–479.
AUTHORS:
1. Sreenivas N.
2. Kunal Puri
3. Shubha Jayaram
PARTICULARS OF CONTRIBUTORS:
1. Associate Professor, Department of
Pathology, Mysore Medical College &
Research Institute, Mysore.
2. Post Graduate, Department of
Pathology, Mysore Medical College &
Research Institute, Mysore.
3. Associate Professor, Department of
Biochemistry, Mysore Medical College &
Research Institute, Mysore.
NAME ADDRESS EMAIL ID OF THE
CORRESPONDING AUTHOR:
Dr. Sreenivas N,
Associate Professor,
Department of Pathology,
Mysore Medical College &
Research Institute, Mysore.
E-mail: sreenivassimha@rediffmail.com
Date
Date
Date
Date
of
of
of
of
Submission: 11/02/2015.
Peer Review: 13/02/2015.
Acceptance: 25/02/2015.
Publishing: 27/02/2015.
J of Evidence Based Med & Hlthcare, pISSN- 2349-2562, eISSN- 2349-2570/ Vol. 2/Issue 9/Mar 02, 2015
Page 1334
Download